Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 10/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | SI | P14410 | 3/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21945753 | 0.86 | SRD5A2 (0.44) | SRD5A2 | |
| SCHEMBL21945695 | 0.84 | NR1H2 (0.40) | NPC1RAB9ASRD5A2 | |
| SCHEMBL18004182 | 0.83 | ESRRA (0.41) | ESRRAFFAR1FFAR2FFAR4MEN1 | |
| SCHEMBL26070335 | 0.79 | QPCT (0.32) | — | |
| SCHEMBL26070378 | 0.78 | MRGPRX4 (0.43) | MRGPRX4GAA | |
| SCHEMBL21945735 | 0.77 | PRMT6 (0.34) | MEN1KMT2AMRGPRX4 | |
| SCHEMBL26070309 | 0.76 | SRD5A2 (0.34) | FFAR1FFAR4MRGPRX4SRD5A2 | |
| SCHEMBL21944776 | 0.74 | MRGPRX4 (0.48) | MRGPRX4 | |
| SCHEMBL21944756 | 0.73 | ABCC8 (0.32) | — | |
| SCHEMBL21944841 | 0.71 | C5AR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | ESRRA 1413/4885FFAR1 1292/4885FFAR2 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.